Cancer patients can respond very differently to the same treatment, while current testing may not reliably identify the therapy most likely to work for each tumor.
R&D Focus
Liquid biopsy and molecular residual disease monitoring
Innovative Solution
Wholomics specializes in developing minimally-invasive liquid biopsy tests for cancer detection and precision medicine.
People
Founders
Maximilian Schneider
About
Wholomics specializes in developing minimally-invasive liquid biopsy tests for cancer detection and precision medicine.
Products
Demo Product or Complete Product?
Development stage
Something missing or incorrect on this page? Help us enrich this information
